Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.
Saved in:
| Title: | Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis. |
|---|---|
| Authors: | Liu YL; Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill Cornell Medical College, New York, New York, USA., Mathews CA; Program in Women's Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Legoretta Cancer Center, Brown University, Providence, Rhode Island, USA., Simpkins F; Department of Obstetrics and Gynecology, Jordan Center for Gynecologic Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Cadoo KA; Memorial Sloan Kettering Cancer Center, New York, New York, USA.; St. James's Hospital Dublin, Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, Ireland., Provencher D; Division of Gynecologic-Oncology, Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada., McCormick CC; Legacy Medical Group Gynecologic Oncology, Portland, Oregon, USA.; The Johns Hopkins Hospital, Baltimore, Maryland, USA., ElNaggar AC; West Cancer Center and Research Institute, Memphis, Tennessee, USA., Altman AD; CancerCare Manitoba, Research Institute of Oncology and Hematology, University of Manitoba, Winnipeg, Manitoba, Canada., Gilbert L; Division of Gynecologic Oncology, McGill University Health Centre and The Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada., Black D; Willis-Knighton Cancer Center, Shreveport, Louisiana, USA., Kabil N; AstraZeneca, Gaithersburg, Maryland, USA., Taylor RN; AstraZeneca, Cambridge, UK., Barnicle A; AstraZeneca, Cambridge, UK., Munley JY; AstraZeneca, Wilmington, Delaware, USA., Aghajanian C; Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill Cornell Medical College, New York, New York, USA. |
| Source: | Cancer [Cancer] 2025 Jan 15; Vol. 131 (2), pp. e35707. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.35707 |
